Use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation across five stages of chronic kidney diseases

2 September 2024 (08:51 - 09:03)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Tze-Fan Chao

Taipei Veterans General Hospital, Taipei (Taiwan)

4 More presentations in this session

Presentation thumbnail

Predictors and outcomes of intracranial hemorrhage in 58,000 patients with atrial fibrillation on oral anticoagulation: insights from COMBINE-AF

Doctor M. Tannu (Durham, US)

Abstract Slides Video

Presentation thumbnail

Anticoagulation and stroke in hospitalized patients newly diagnosed with secondary atrial fibrillation: a population-based cohort study

Doctor H. Abdel-Qadir (Toronto, CA)

Abstract Slides Video

Presentation thumbnail

Post-operative atrial fibrillation during cardiac rehabilitation: incidence and long-term prognostic value.

Doctor S. Rastelli (IT)

Abstract Slides Video

Presentation thumbnail

Risk of thromboembolic and haemorrhagic events associated with anticoagulation among 11,355 patients with non-valvular atrial fibrillation and thrombocytopenia

Doctor M. Tam (Shatin, HK)

Abstract Slides Video

Access the full session

Session thumbnail

Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations

The Event

Event poster

ESC Congress 2024

2 September 2024 08:51 CET

You may be interested in

Congress Presentation

Stroke, mortality, and major bleeding among patients with atrial fibrillation and chronic kidney disease; insights from a contemporary large-scale population study

Congress Session

Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations

Congress Presentation

Atrial fibrillation and chronic kidney failure: who and how to anticoagulate

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources